[Molecular targeted therapies].
Current treatment paradigms in cancer patients are shifting from cytotoxic chemotherapies alone to single-agent and combination biological and targeted therapies. Targeted therapies are entering standard treatment paradigms. As patient responses to targeted therapies vary, predictive biomarkers will be an important tool of a patient's diagnostic workup in personalized medicine. This review provides a broad overview of molecular targeted agents, and highlight biomarkers, including novel adaptive clinical trial designs, incorporating putative biomarkers into prospective clinical trials.
Kimura
Hideharu
H
Department of Genome Biology, Kinki University School of Medicine.
Nishio
Kazuto
K
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000954:Antigens, Surface / Q000276:immunology; D000068258:Bevacizumab; D014408:Biomarkers, Tumor; D002986:Clinical Trials as Topic; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D000069283:Rituximab
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000954:Antigens, Surface; D014408:Biomarkers, Tumor; D004791:Enzyme Inhibitors; D000068258:Bevacizumab; D000069283:Rituximab; D011505:Protein-Tyrosine Kinases